Gazyva is the first type II, glycoengineered antibody to target cells that have the CD20 marker on their surface. These cells are central to many blood cancers, including common forms of lymphoma and leukemia. Gazyva attacks these cells both directly and together with the body’s immune system.
In the United States, Europe and in additional countries, Gazyva is approved in combination with chlorambucil for the treatment of patients with previously untreated chronic lymphocytic leukemia. In Europe and Switzerland, Gazyva is marketed as Gazyvaro.
This medicinal product is subject to additional monitoring. This will allow quick identification of new safety information. Healthcare professionals and patients are asked to report any suspected adverse reactions. See our information for details on how to report.